Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Stephen Salloway, MD, Brown University, Butler Hospital, Providence, RI, discusses the new developments in amyloid-targeting antibodies for Alzheimer’s disease. Currently, there are three medicines in development that have progressed significantly: lecanemab, donanemab, and gantenerumab. Lecanemab is under review by the FDA for accelerated approval, with announcements on its status to occur in early 2023. Data from the Phase III clinical trials of gantenerumab and lecanemab will be reported in November 2023. This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA.